Aug 19, 2020 8:30am EDT Sapience Therapeutics Awarded SBIR Phase I Grant from National Cancer Institute
Aug 12, 2020 8:30am EDT Sapience Therapeutics Announces First Patient Dosed with ST101 in Phase 1/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors
Jun 17, 2020 8:30am EDT Sapience Therapeutics to Present Data on its Two Lead Programs at 2020 AACR Virtual Annual Meeting II
Jun 02, 2020 8:30am EDT Sapience Therapeutics Announces FDA Acceptance of IND Application for ST101 in Advanced Cancer Indications
May 07, 2020 8:30am EDT Sapience Therapeutics Receives United Kingdom Authorization to Initiate a Phase 1/2 Trial of Lead Candidate ST101 in Advanced Cancer Indications
